|
Catalog #
|
Source:
|
Lot #
|
Size:
|
|
AP1806a
|
Rabbit
|
SA090120AA
|
0.1 mg
|
|
Concentration:
|
Accession:
|
Clone Name:
|
Isotype:
|
|
0.25 mg/ml
|
NP_073729, Q9GZQ8
|
RB15842
|
Rabbit Ig
|
|
Applications:
|
Reactivity:
|
MW (kDa):
|
|
WB, IF, ICC, IHC, E
|
H, M, B*, C*, R*
|
14557 Da
|
|
Target/Specificity:
|
|
This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide at the C-terminal cleavage site of human cleaved-LC3 (APG8b).
|
|
Other Names:
|
|
Microtubule-associated proteins 1A/1B light chain 3B [Precursor]; MAP1A/MAP1B LC3 B; MAP1A/1B light chain 3 B; MAP1 light chain 3-like protein 2; Autophagy-related protein LC3 B; Autophagy-related ubiquitin-like modifier LC3 B; MAP1LC3B; MAP1ALC3
|
|
Application Data:
|
(LEFT) Western blot analysis of anti-cleaved-LC3 (APG8b) Pab (Cat. #AP1806a) in 293 cell line lysates transiently transfected with the LC3 (APG8b) gene (2ug/lane). Cleaved-LC3 (APG8b) (arrow) was detected using the purified Pab (1:60 dilution).
(RIGHT) The anti-LC3 (APG8b) Pab (Cat. #AP1806a) is used in Western blot to detect LC3 (APG8b) in mouse brain tissue lysate. LC3 (APG8b) (arrow) was detected using the purified Pab. |
TOP: Time course study of mouse leukaemic monocyte macrophage cells treated with U18666A, a drug that causes cholesterol and lipid storage in cells, thereby blocking fusion between late endosomes and lysosomes. Cleaved-LC3 (APG8b) antibody (Cat AP1806a) detected punctuate staining indicative of autophagic vacuole or phagosome structures. Data courtesy of Dr. Barry Boland, Department of Pharmacology, Oxford University. MIDDLE: SY5Y cells were pretreated with 5nM bafilomycin for 24hr and fixed in methanol (left panel) or 4% of paraformaldehyde (right panel). Treatment with Cat# AP1806a antibody at dilution 1:100. Data courtesy of Jianhui Zhu, MD, PhD & Charleen T. Chu, MD, PhD, University of Pittsburgh School of Medicine. BOTTOM: Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma. Time course study of mouse leukaemic monocyte macrophage cells treated with U18666A, a drug that causes cholesterol and lipid storage in cells, thereby blocking fusion between late endosomes and lysosomes. Cleaved-LC3 (APG8b) antibody (Cat AP1806a) detected punctuate staining indicative of autophagic vacuole or phagosome structures. Data courtesy of Dr. Barry Boland, Department of Pharmacology, Oxford University. |
|
|
Background:
|
|
Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). MAP1A and MAP1B are microtubule-associated proteins which mediate the physical interactions between microtubules and components of the cytoskeleton. These proteins are involved in formation of autophagosomal vacuoles (autophagosomes). MAP1A and MAP1B each consist of a heavy chain subunit and multiple light chain subunits. MAP1LC3b is one of the light chain subunits and can associate with either MAP1A or MAP1B. The precursor molecule is cleaved by APG4B/ATG4B to form the cytosolic form, LC3-I. This is activated by APG7L/ATG7, transferred to ATG3 and conjugated to phospholipid to form the membrane-bound form, LC3-II.
|
|
Background References:
|
- Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005)
- Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005)
- Greenberg JT. Dev Cell. 8(6):799-801. (2005)
- Levine B. Cell. 120(2):159-62. (2005)
- Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)
- Tanida I., et al. Int. J. Biochem. Cell Biol. 36:2503-2518(2004)
- He H., et al. J. Biol. Chem. 278:29278-29287(2003)
- Tanida I., et al. J. Biol. Chem. 279:36268-36276(2004)
|
|
Product Citations:
|
|
|
|
Application Notes:
|
| The suggested dilution is: | |
| ELISA | 1:1,000 |
| Western blotting | 1:100~500 |
| Immunohistochemistry | 1:100 |
| Immunocytochemistry | 1:50~100 |
|
|
Format:
|
|
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
|
|
Storage:
|
|
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
|
|
Precautions:
|
|
This product is for research use only. Not for use in diagnostic
or therapeutic procedures.
|
